A study from Washington University School of Medicine in St. Louis identifies a potential breakthrough in treating age-related macular degeneration by targeting cholesterol metabolism problems that contribute to vision loss in people over 50. Researchers found that patients with macular degeneration have reduced levels of apolipoprotein M (ApoM) in their blood, a molecule that plays a crucial role in processing “good cholesterol” and clearing harmful cholesterol deposits from cells.
When ApoM levels are low, cholesterol accumulates in retinal cells, leading to inflammation and cellular damage that causes vision loss. In mouse studies, increasing ApoM levels through genetic modification or plasma transfer improved retinal health, enhanced light-sensing cell function, and reduced cholesterol deposits in the eyes. The findings, published in Nature Communications, suggest that developing treatments to boost ApoM levels could potentially treat or even prevent macular degeneration, offering hope for preserving vision as people age.